508 related articles for article (PubMed ID: 37176138)
1. New Insight into the Molecular Pathomechanism and Immunomodulatory Treatments of Hidradenitis Suppurativa.
Molinelli E; Gioacchini H; Sapigni C; Diotallevi F; Brisigotti V; Rizzetto G; Offidani A; Simonetti O
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176138
[TBL] [Abstract][Full Text] [Related]
2. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
[TBL] [Abstract][Full Text] [Related]
3. Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis.
Goldburg SR; Strober BE; Payette MJ
J Am Acad Dermatol; 2020 May; 82(5):1045-1058. PubMed ID: 31604104
[TBL] [Abstract][Full Text] [Related]
4. Long-standing refractory hidradenitis suppurativa responded to a brodalumab monotherapy in a patient with psoriasis: A possible involvement of Th17 across the spectrum of both diseases.
Yoshida Y; Oyama N; Iino S; Shimizu C; Hasegawa M
J Dermatol; 2021 Jun; 48(6):916-920. PubMed ID: 33609416
[TBL] [Abstract][Full Text] [Related]
5. Biologics for hidradenitis suppurativa: an update.
Włodarek K; Ponikowska M; Matusiak Ł; Szepietowski JC
Immunotherapy; 2019 Jan; 11(1):45-59. PubMed ID: 30702012
[TBL] [Abstract][Full Text] [Related]
6. Narrative Review and Update on Biologic and Small Molecule Drugs for Hidradenitis Suppurativa: An Entity With a Promising Future.
Mansilla-Polo M; Escutia-Muñoz B; Botella-Estrada R
Actas Dermosifiliogr; 2023 Oct; 114(9):T772-T783. PubMed ID: 37541580
[TBL] [Abstract][Full Text] [Related]
7. Narrative Review and Update on Biologic and Small Molecule Drugs for Hidradenitis Suppurativa: An Entity With a Promising Future.
Mansilla-Polo M; Escutia-Muñoz B; Botella-Estrada R
Actas Dermosifiliogr; 2023 Oct; 114(9):772-783. PubMed ID: 37211274
[TBL] [Abstract][Full Text] [Related]
8. New and Emerging Targeted Therapies for Hidradenitis Suppurativa.
Markota Čagalj A; Marinović B; Bukvić Mokos Z
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409118
[TBL] [Abstract][Full Text] [Related]
9. An Update on Current Clinical Management and Emerging Treatments in Hidradenitis Suppurativa.
Miller A; Shahzeidi P; Bernhardt M
Skin Therapy Lett; 2024 Mar; 29(2):1-6. PubMed ID: 38574201
[TBL] [Abstract][Full Text] [Related]
10. Hidradenitis suppurativa: A practical review of possible medical treatments based on over 350 hidradenitis patients.
Scheinfeld N
Dermatol Online J; 2013 Apr; 19(4):1. PubMed ID: 24021361
[TBL] [Abstract][Full Text] [Related]
11. Secukinumab in the treatment of hidradenitis suppurativa.
Snyder CL; Gibson RS; Porter ML; Kimball AB
Immunotherapy; 2023 Dec; 15(17):1449-1457. PubMed ID: 37840286
[TBL] [Abstract][Full Text] [Related]
12. Biologics for Hidradenitis suppurativa: evolution of the treatment paradigm.
Maronese CA; Moltrasio C; Genovese G; Marzano AV
Expert Rev Clin Immunol; 2024 May; 20(5):525-545. PubMed ID: 38130204
[TBL] [Abstract][Full Text] [Related]
13. Hidradenitis suppurativa: guidelines of the Italian Society of Dermatology and Venereology (SIDeMaST) for the use of anti-TNF-α agents.
Megna M; Bettoli V; Chimenti S; Chiricozzi A; Naldi L; Virgili A; Girolomoni G; Monfrecola G
G Ital Dermatol Venereol; 2015 Dec; 150(6):731-9. PubMed ID: 26513043
[TBL] [Abstract][Full Text] [Related]
14. Novel Therapeutic Approaches and Targets for the Treatment of Hidradenitis Suppurativa.
Giuffrida R; Cannavò SP; Coppola M; Guarneri C
Curr Pharm Biotechnol; 2021; 22(1):59-72. PubMed ID: 32368973
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological development in hidradenitis suppurativa.
Matusiak Ł; Jemec GB; Szepietowski JC
Curr Opin Pharmacol; 2019 Jun; 46():65-72. PubMed ID: 31075754
[TBL] [Abstract][Full Text] [Related]
16. Paradoxical Hidradenitis Suppurativa during Biologic Therapy, an Emerging Challenge: A Systematic Review.
Ruggiero A; Martora F; Picone V; Marano L; Fabbrocini G; Marasca C
Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203664
[TBL] [Abstract][Full Text] [Related]
17. Hidradenitis suppurativa: Current and emerging treatments.
Goldburg SR; Strober BE; Payette MJ
J Am Acad Dermatol; 2020 May; 82(5):1061-1082. PubMed ID: 31604100
[TBL] [Abstract][Full Text] [Related]
18. Advances in biologic and small molecule therapies for hidradenitis suppurativa.
Chen SX; Greif C; Gibson RS; Porter ML; Kimball AB
Expert Opin Pharmacother; 2022 Jun; 23(8):959-978. PubMed ID: 35470765
[TBL] [Abstract][Full Text] [Related]
19. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life.
Nguyen TV; Damiani G; Orenstein LAV; Hamzavi I; Jemec GB
J Eur Acad Dermatol Venereol; 2021 Jan; 35(1):50-61. PubMed ID: 32460374
[TBL] [Abstract][Full Text] [Related]
20. A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs.
Holcomb ZE; Porter ML; Kimball AB
Expert Opin Drug Saf; 2021 Oct; 20(10):1147-1161. PubMed ID: 33910441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
